Screening for Type 2 Diabetes Mellitus: 10-Year Mortality Not Improved
Am Fam Physician. 2013 Apr 1;87(7):510.
Are high-risk patients who are screened for diabetes mellitus better off than patients who are diagnosed through the usual means?
Screening high-risk patients for diabetes provides no 10-year mortality benefit. The findings of this study are consistent with those of another large study of screening for type 2 diabetes (http://www.essentialevidenceplus.com/content/poem/130943 [subscription required]). Perhaps it is time to stop screening patients for diabetes and use our limited resources on endeavors that make a difference, like smoking cessation. (Level of Evidence = 1b)
Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet.. 2012; 380( 9855): 1741– 1748.
Study design: Other
Funding source: Foundation Allocation: Uncertain
Setting: Outpatient (primary care)
These British researchers conducted a cluster randomized trial of screening for type 2 diabetes. Fifteen general practices were to screen and intensively treat adults with diabetes, 13 practices were to screen and treat patients according to national guidelines, and five practices were left to their own devices. One practice dropped out before screening commenced. Overall, more than 20,000 high-risk adults 40 to 69 years of age were included and followed for an average of 10 years. The authors used national databases to determine if any of the patients had died during the study period. Among the screening practices, 94 percent of potentially eligible patients were invited to participate, 75 percent were screened, and 3 percent were found to have diabetes. The overall death rate in the group of screened patients was 10.5 (per 1,000 person-years) compared with 9.9 in unscreened patients. Additionally, there were no differences in cardiovascular deaths (3.3 and 3.2, respectively) or cancer-related deaths (4.8 and 4.4, respectively).
POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Jan 15, 2020
Access the latest issue of American Family Physician